Compare Johnson & Johnson (JNJ) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Newegg Commerce Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Newegg Commerce Inc trades at $11.58 (market cap $243.30M). The key difference: Johnson & Johnson is far larger — about 2540.4× Newegg Commerce Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Newegg Commerce Inc for 14 Days on average.
| JNJ | NEGG | |
|---|---|---|
Market Cap | $618.09B | $243.30M |
Volume | 6,050,983 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $92.74 |
52-Week Low | $186.00 | $11.49 |
Typical Hold Time | 129 Days | 14 Days |
Enterprise Value | $646.37B | $213.53M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
NEGG trades at $11.58, down 3.58% on the day, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.11 versus a -$0.40 estimate. The company shows improving fundamentals, with revenue stabilizing around $1.4B and net losses narrowing significantly in 2025. New partnerships with Western Digital and Hewlett Packard Enterprise highlight strategic moves in IT infrastructure.
The outlook is mixed; improving profitability and low P/S ratio offer value, but negative operating cash flow and insider selling pose risks. Analyst consensus is a Buy with a $7.75 target, below the current price, indicating caution. Key risks include competitive pressures and reliance on financing activities for liquidity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
